menu

International Call for Biosimilar Investigators

Quintiles is growing our investigator network to meet global demands to conduct biosimilar trials across a range of therapy areas. Whether you are already a Quintiles investigator or new to Quintiles, register your interest in becoming an investigator on biosimilar trials today!

  • If you are a Quintiles investigator with an Infosario® account, click here to log in and update your Investigator Profile.
       (Go to the section titled, Biologics & Biosimilars.)
  • If you are a Quintiles investigator but do not have an Infosario® account, click here.
  • If you are new to Quintiles, click here.
By registering, investigators will receive our newsletter Biosimilar News Brief highlighting developments within the biosimilar industry in your region and around the world.


Why should I partner with Quintiles?   +

Quintiles has:

  • helped to develop or commercialize:
    • 100% of the top 50 best-selling biotechnology products or compounds of 2013
    • 90% of the new Biologic License Applications approved by the US FDA between 2004 and 2013.
  • supported the development of biosimilars for more than 10 different originator biologics including monoclonal antibodies.
  • established Biosimilars Knowledge Connect to educate and engage investigators in biosimilars research.

Quintiles is your ideal clinical research partner in biosimilars development. We work with tens of thousands of research sites around the world and consistently demonstrate high standards of quality assurance and good clinical practice. We aim to offer investigators a high-quality and rewarding experience.

Why should I become a biosimilars investigator and enroll my patients in biosimilar trials?   +

The development of biosimilars is an emerging field with the exciting prospect of bringing lower-cost biologics to market. At Quintiles, we believe there are a number of important benefits – both immediate and longer-term – which make participation in biosimilars research worthwhile.

You can:
Your patients can:
  • Help to improve patient access to vital biologics worldwide.
  • Gain personal experience with a biosimilar before approval.
  • Collect clinical data on local populations.
  • Publish the findings of your research and establish expertise in an expanding field of drug development.
  • Influence the decisions of medical colleagues and payers in the biosimilars field.
  • Ensure optimal patient safety through maintaining high quality clinical testing.
  • Gain immediate access to active biologic medication (either the branded originator or a biosimilar candidate) at no cost to them or their insurers.
  • Be assured of a relatively low risk of treatment failure because clinical trials use the approved regimen for the licensed originator biologic.
  • Receive comprehensive care from a specialist team throughout the trial.
  • Contribute to improved access to biologics for future patients.


Why did Quintiles launch Biosimilars Knowledge Connect?   +

In 2012, Quintiles conducted a global survey of clinical investigators and found that more than 75% were interested in participating in biosimilar research, but still had a number of questions and concerns regarding the official definition of ‘similarity’, how this standard is enforced by regulatory authorities, whether licensed biosimilars are really safe to prescribe and the potential benefits of patient participation in biosimilar studies.

To address the need for education, Quintiles launched Biosimilars Knowledge Connect, a global initiative to inform investigators about biosimilars and their role in improving patient access to potentially life-saving biologic medicines. This initiative included personal outreach to investigators working with Quintiles, as well as the development of this website and a number of other educational resources that you can find within the Resources section.

References   +

1. US$67 billion worth of biosimilar patents expiring before 2020. Generics and Biosimilars Initiative, 20 January 2014. http://www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020/(highlight)/67%20billion. Accessed 16 September 2014.
2. Barclays Capital, 2011. European pharmaceuticals. Biosimilars: Opportunity or threat? The Biosimilars Handbook.
3. Thomson Reuters BioWorld, 2014. Biosimilars: A global perspective of a new market opportunities, threats and critical strategies. http://www.bioworld.com/content/biosimilars-global-perspective-new-market-opportunities-threats-and-critical-strategies-2014. Accessed 24 November 2014.
4. European Commission, 2013. Consensus Information Document. What you need to know about Biosimilar Medicinal Products.
5. IMS Health Thought Leadership, November 2013. The global use of medicines: Outlook through 2017. Report by the IMS Institute for Healthcare Informatics.
6. RnR Market Research 11 February 2014. Global biosimilars market expected to witness steady growth. http://www.rnrmarketresearch.com/blog/global-biosimilars-market-expected-to-witness-steady-growth.html. Accessed 24 November 2014.
7. Frost & Sullivan, 16 January 2014. Analysis of the global biosimilars market. http://www.frost.com/sublib/display-report.do?id=M95E-01-00-00-00. Accessed 24 November 2014.
Video Spotlights
Quintiles perspective: Why should sites get involved in biosimilar clinical trials?
Quintiles perspective: Why should sites get involved in biosimilar clinical trials?
Quintiles perspective: What are the benefits of getting involved in biosimilar clinical trials?
Quintiles perspective: What are the benefits of getting involved in biosimilar clinical trials?
Quintiles perspective: How can patients benefit from biosimilars clinical research?
Quintiles perspective: How can patients benefit from biosimilars clinical research?